Structural Modulation Study of Inhibitory Compounds for Ribonuclease H Activity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase

被引:0
作者
Yanagita, Hiroshi [1 ]
Fudo, Satoshi [1 ]
Urano, Emiko [2 ]
Ichikawa, Reiko [2 ]
Ogata, Masakazu [1 ]
Yokota, Mizuho [1 ]
Murakami, Tsutomu [2 ]
Wu, Honggui [2 ,3 ]
Chiba, Joe [3 ]
Komano, Jun [2 ]
Hoshino, Tyuji [1 ]
机构
[1] Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan
[2] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan
[3] Tokyo Univ Sci, Fac Ind Sci & Technol, Noda, Chiba 2788510, Japan
基金
日本学术振兴会;
关键词
antiviral drug; ribonuclease H enzymatic activity; nitro-furan-phenyl-ester; human immunodeficiency virus type 1 reverse transcriptase; inhibitor; HIV RNASE-H; DRUG-RESISTANCE; RECENT PROGRESS; DIKETO ACID; DNA; SITE; MECHANISM; PREDICTION; CATALYSIS; COMPLEX;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Reverse transcriptase of human immunodeficiency virus type 1 (HIV-1) has two enzymatic functions. One of the functions is ribonuclease (RNase) H activity concerning the digestion of only RNA of RNA/DNA hybrid. The RNase H activity is an attractive target for a new class of anti-HIV drugs because no approved inhibitor is available now. In our previous studies, an agent bearing 5-nitro-furan-2-carboxylic acid ester core was found from chemical screening and dozens of the derivatives were synthesized to improve compound potency. In this work, some parts of the chemical structure were modulated to deepen our understanding of the structure activity relationship of the analogous compounds. Several derivatives having nitrofuran-phenyl-ester skeleton were shown to be potent RNase H inhibitors. Attaching methoxy-carbonyl and methoxy groups to the phenyl ring increased the inhibitory potency. No significant cytotoxicity was observed for these active derivatives. In contrast, the derivatives having nitro-furan-benzyl-ester skeleton showed modest inhibitory activities regardless of attaching diverse kinds of functional groups to the benzyl ring. Both the modulation of the 5-nitro-furan-2-carboxylic moiety and the conversion of the ester linkage resulted in a drastic decrease in inhibitory potency. These findings are informative for designing potent inhibitors of RNase H enzymatic activity of HIV-1.
引用
收藏
页码:764 / 771
页数:8
相关论文
共 50 条
  • [21] Dipyridodiazepinone Analogs as Human Immunodeficiency Virus Type 1-Specific Non-Nucleoside Reverse Transcriptase Inhibitors: An Overview
    Lv, M.
    Xu, H.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (18) : 1874 - 1898
  • [22] Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors
    Kayondo, Jonathan K.
    Ndembi, Nicaise
    Parry, Chris M.
    Cane, Patricia A.
    Hue, Stephane
    Goodall, Ruth
    Dunn, David T.
    Kaleebu, Pontiano
    Pillay, Deenan
    Mbisa, Jean L.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2015, 31 (07) : 749 - 756
  • [23] Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors
    Domaoal, RA
    Demeter, LM
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (09) : 1735 - 1751
  • [24] Identification of a Non-Nucleoside Reverse Transcriptase Inhibitor against Human Immunodeficiency Virus-1
    Kim, Min-Jung
    Yu, Kyung Lee
    Han, Ri
    Lee, Yoonji
    Oh, Kyungsoo
    You, Ji Chang
    ACS INFECTIOUS DISEASES, 2023, 9 (08): : 1582 - 1592
  • [25] An in silico molecular modeling approach of halolactone derivatives as potential inhibitors for human immunodeficiency virus type-1 reverse transcriptase enzyme
    Lima da Costa, Ana Paula
    Bonfim Cardoso, Fabio Jose
    de Molfetta, Fabio Alberto
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (05) : 1715 - 1729
  • [26] A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
    Winters, MA
    Coolley, KL
    Girard, YA
    Levee, DJ
    Hamdan, H
    Shafer, RW
    Katzenstein, DA
    Merigan, TC
    JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (10) : 1769 - 1775
  • [27] Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
    Selhorst, Philippe
    Vazquez, Ana C.
    Terrazas-Aranda, Katty
    Michiels, Johan
    Vereecken, Katleen
    Heyndrickx, Leo
    Weber, Jan
    Quinones-Mateu, Miguel E.
    Arien, Kevin K.
    Vanham, Guido
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (04) : 1403 - 1413
  • [28] NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine
    Paolucci, Stefania
    Baldanti, Fausto
    Campanini, Giulia
    Cancio, Reynel
    Belfiore, Amalia
    Maga, Giovanni
    Gerna, Giuseppe
    ANTIVIRAL RESEARCH, 2007, 76 (02) : 99 - 103
  • [29] Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients
    Dunn, Linda L.
    Boyer, Paul L.
    McWilliams, Mary Jane
    Smith, Steven J.
    Hughes, Stephen H.
    VIROLOGY, 2015, 484 : 127 - 135
  • [30] Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1
    Coutsinos, Dimitrios
    Invernizzi, Cedric F.
    Xu, Hongtao
    Moisi, Daniela
    Oliveira, Maureen
    Brenner, Bluma G.
    Wainberg, Mark A.
    JOURNAL OF VIROLOGY, 2009, 83 (04) : 2029 - 2033